特发性肺纤维化(IPF)是一种致死性疾病.其发病率高,总体预后差,自然病程差异很大,目前缺乏有效的治疗手段.近年来,IPF生物标志物已成为人们关注和研究的热点.良好的预后生物标志物可以协助判断疾病的结局,预测疾病的转归.基因变异如MUC5B、TLR3与患者预后相关;淋巴细胞染色体端粒长度缩短与患者生存率存在一定的相关性;血清中KL-6、SP-A、SP-D、MMP7和CXCL13水平升高提示患者预后差.目前IPF预后相关的生物标志物研究已取得不少成果,本文就IPF预后生物标志物的研究进展进行综述.%Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease,associated with high morbidity and poor prognosis,and the clinical course is highly variable.At present,there is no effective treatment for this disease.In recent years,biomarkers for IPF has become a hot research topic.Good prognostic biomarkers would be contributed to estimate the finality and predict the prognosis of this disease.Patients carry with genovariation such as MUC5B and TLR3 have relation with the prognosis of the disease.Short telomere length has a certain correlation with survival rate in IPF.The increased serum levels of several proteins including KL-6,SP-A,SP-D,MMP7 and CXCL13 have been associated with poor outcome.This article aims to provide an overview of recent developments in prognostic biomarkers for IPF.
展开▼
